Blood eosinophils in COPD to predict exacerbations and inform inhaled corticosteroid use: Need for further evidence?

References

• Adeloye D, Chua S, Lee C, Global Health Epidemiology Reference Group (GHERG), et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi:10.7189/jogh.05-020415.
   PubMed Web of Science ®Google Scholar
• https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. In.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2019 Report. In 2019.
   Google Scholar
• Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther. 2019;198:160–188. doi:10.1016/j.pharmthera.2019.02.013.
   PubMed Web of Science ®Google Scholar
• Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol. 2012;11:132 doi:10.1186/1475-2840-11-132.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5(9):747–759. doi:10.1016/S2213-2600(17)30217-5.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Pavord ID, Landis S, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2018;138:21–31. doi:10.1016/j.rmed.2018.03.016.
   PubMed Web of Science ®Google Scholar
• Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341–1351. doi:10.1016/S0140-6736(11)60968-9.
   PubMed Web of Science ®Google Scholar
• Matera MG, Cardaci V, Cazzola M, Rogliani P. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(4):533–541. doi:10.1517/14740338.2015.1001363.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–459. doi:10.1146/annurev.pathol.4.110807.092145.
   PubMed Web of Science ®Google Scholar
• Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445–2454. doi:10.1056/NEJMra0804752.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672–688. doi:10.1183/09031936.03.00040703.
   PubMed Web of Science ®Google Scholar
• Opitz B, van Laak V, Eitel J, Suttorp N. Innate immune recognition in infectious and noninfectious diseases of the lung. Am J Respir Crit Care Med. 2010;181(12):1294–1309. doi:10.1164/rccm.200909-1427SO.
   PubMed Web of Science ®Google Scholar
• Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39–47. doi:10.2147/copd.2006.1.1.39.
   PubMedGoogle Scholar
• Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9–22. doi:10.1038/nri3341.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. CTS position statement: Pharmacotherapy in patients with COPD—An update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2017;1(4):222–241. doi:10.1080/24745332.2017.1395588.
   Web of Science ®Google Scholar
• Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44(7):946–953. doi:10.1016/j.ejca.2008.03.006.
   PubMed Web of Science ®Google Scholar
• Masucci GV, Cesano A, Hawtin R, et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer. 2016;4:76 doi:10.1186/s40425-016-0178-1.
   PubMed Web of Science ®Google Scholar
• Dobbin KK, Cesano A, Alvarez J, et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations. J Immunother Cancer. 2016;4:77 doi:10.1186/s40425-016-0179-0.
   PubMed Web of Science ®Google Scholar
• Greulich T, Mager S, Lucke T, et al. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2018;13:2999–3002. Vol New Zealand doi:10.2147/COPD.S165909.
   PubMed Web of Science ®Google Scholar
• Landis SH, Suruki R, Hilton E, Compton C, Galwey NW. Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink. Copd. 2017;14(4):382–388. doi:10.1080/15412555.2017.1313827.
   Google Scholar
• Oshagbemi OA, Burden AM, Braeken DCW, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195(10):1402–1404. doi:10.1164/rccm.201701-0009LE.
   PubMed Web of Science ®Google Scholar
• Kreindler JL, Watkins ML, Lettis S, Tal-Singer R, Locantore N. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD . BMJ Open Respir Res. 2016;3(1):e000151 doi:10.1136/bmjresp-2016-000151.
   PubMed Web of Science ®Google Scholar
• Schumann DM, Tamm M, Kostikas K, Stolz D. Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest. 2019;156(3):456–465. doi:10.1016/j.chest.2019.04.012.
   PubMed Web of Science ®Google Scholar
• Tavernier G, Fowler SJ, Allen D, Simpson A, Durrington H, Niven R. Sputum eosinophils vary by time of day in severe asthma: Implications for management. European Respiratory Journal. 2018;52(suppl 62):PA5033. doi:10.1183/13993003.congress-2018.PA5033.
   Google Scholar
• Durrington HJ, Gioan-Tavernier GO, Maidstone RJ, et al. Time of day affects eosinophil biomarkers in asthma: Implications for diagnosis and treatment. Am J Respir Crit Care Med. 2018;198(12):1578–1581. doi:10.1164/rccm.201807-1289LE.
   PubMed Web of Science ®Google Scholar
• Anand A, Ahmed O, Pavord ID, McClure M, Ferry B, Pavord SR. P70 Blood eosinophil counts in normal controls with no history of allergic disease. Thorax. 2015;70(Suppl 3):A111–A111. doi:10.1136/thoraxjnl-2015-207770.207.
   Google Scholar
• DiSantostefano RL, Hinds D, Le HV, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir Med. 2016;112:88–96. doi:10.1016/j.rmed.2016.01.013.
   PubMed Web of Science ®Google Scholar
• Cheng SL. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. COPD. 2018;13:2775–2784. doi:10.2147/COPD.S175017.
   Google Scholar
• Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. COPD. 2016;11:1495–1504. doi:10.2147/COPD.S100338.
   Google Scholar
• Eltboli O, Mistry V, Barker B, Brightling CE. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology. 2015;20(4):667–670. doi:10.1111/resp.12475.
   PubMed Web of Science ®Google Scholar
• Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-0.
   PubMed Web of Science ®Google Scholar
• Bathoorn E, Liesker JJ, Postma DS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009;4:101–109. doi:10.2147/copd.s4854.
   PubMedGoogle Scholar
• Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J. 2005;25(4):640–646. doi:10.1183/09031936.05.00047504.
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The copenhagen general population study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC.
   PubMed Web of Science ®Google Scholar
• Yun JH, Lamb A, Chase R, COPDGene and ECLIPSE Investigators, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037–2047.e2010. doi:10.1016/j.jaci.2018.04.010.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–1485. doi:10.1016/S0140-6736(00)02872-5.
   PubMed Web of Science ®Google Scholar
• Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193–198. doi:10.1136/thx.2004.032516.
   PubMed Web of Science ®Google Scholar
• Cheng SL, Wang HH, Lin CH. Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD. COPD. 2017;Volume 12:2231–2238. doi:10.2147/COPD.S140748.
   Google Scholar
• Leung JM, Sin DD. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. BMJ. 2017;358:j3772 doi:10.1136/bmj.j3772.
   PubMed Web of Science ®Google Scholar
• Hines KL, Peebles RS. Jr. Management of the asthma-COPD overlap syndrome (ACOS): a review of the evidence. Curr Allergy Asthma Rep. 2017;17(3):15 doi:10.1007/s11882-017-0683-4.
   Web of Science ®Google Scholar
• Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699–709. doi:10.1016/S2213-2600(19)30176-6.
   PubMed Web of Science ®Google Scholar
• Mkorombindo T, Dransfield M. Eosinophil-guided treatment of COPD exacerbations: unfinished business. Lancet Respir Med. 2019;7(8):647–648. doi:10.1016/S2213-2600(19)30179-1.
   Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. doi:10.1164/rccm.201502-0235LE.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–1162. doi:10.1016/j.rmed.2014.05.013.
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Pavord I, Barnes NC, Lettis S, Guasconi A, Petruzzelli S. LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach. European Respiratory Journal. 2016;48(suppl 60):OA1763. doi:10.1183/13993003.congress-2016.OA1763.
   Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–223. doi:10.1016/S2213-2600(13)70040-7.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-7.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000. doi:10.2165/00003495-200868140-00004.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–565. doi:10.2165/00003495-200969050-00004.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257–268. doi:10.1016/j.rmed.2011.07.020.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax. 2016;71(2):118–125. doi:10.1136/thoraxjnl-2015-207021.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. doi:10.1164/rccm.200707-973OC.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456. doi:10.1016/S0140-6736(03)12459-2.
   PubMed Web of Science ®Google Scholar
• Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015–1026.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Price D, Mezzi K, Fogel R, Banerji D. QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: A pooled analysis of LANTERN and ILLUMINATE. European Respiratory Journal. 2015;46(suppl 59):PA1005. doi:10.1183/13993003.congress-2015.PA1005.
   Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385.
   PubMed Web of Science ®Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME Trial. Am J Respir Crit Care Med. 2017;195(9):1189–1197. doi:10.1164/rccm.201701-0193OC.
   PubMed Web of Science ®Google Scholar
• Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48(2):320–330. doi:10.1183/13993003.02165-2015.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756. doi:10.1016/S2213-2600(19)30190-0.
   PubMed Web of Science ®Google Scholar
• Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. N Engl J Med. 2018;378(18):1723–1724. doi:10.1056/NEJMe1716802.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell'Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855–862. doi:10.1016/S2213-2600(18)30368-0.
   PubMed Web of Science ®Google Scholar
• Liesker JJ, Bathoorn E, Postma DS, Vonk JM, Timens W, Kerstjens HA. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med. 2011;105(12):1853–1860. doi:10.1016/j.rmed.2011.07.002.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-4.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Tetzlaff K, Vogelmeier C, et al. Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(9):1219–1221. doi:10.1164/rccm.201612-2525LE.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): A randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst J, Frent SM, et al. Withdrawal of inhaled corticosteroids from copd patients inhaling long-term triple therapy: The SUNSET Satudy. Paper presented at: A15. ICS in Copd: The Pendulum Keeps Swinging. American Thoracic Society; 2018. A1009–A1009.
   Google Scholar
• Mitchell P, Leigh R. A drug safety review of treating eosinophilic asthma with monoclonal antibodies. Expert Opin Drug Saf. 2019;18(12):1161–1170.
   Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA, Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901. doi:10.1016/S2213-2600(14)70187-0.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023–1034. doi:10.1056/NEJMoa1905248.
   PubMed Web of Science ®Google Scholar
• Izquierdo JL, Cosio BG. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int J Chron Obstruct Pulmon Dis. 2018;13:3539–3547. doi:10.2147/COPD.S175047.
   PubMed Web of Science ®Google Scholar
• Villar-Álvarez F, Moreno-Zabaleta R, Mira-Solves JJ, et al. Do not do in COPD: consensus statement on overuse. Int J Chron Obstruct Pulmon Dis. 2018;13:451–463. doi:10.2147/COPD.S151939.
   Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2020 Report. 2020. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
   Google Scholar